- European Medicines Authority meets again on Wednesday
- EMA trying to finalise the approval of Moderna COVID-19 vaccine
- Look at the latest tweet here
On Wednesday, the European Medicines Authority (EMA) held a meeting to decide if it can the COVID-19 vaccine from Moderna after it had failed to reach a decision earlier this week.
In a tweet the European regulator said, “The meeting of EMA’s human medicines committee (CHMP) to discuss Covid-19 vaccine Moderna has started,”.
The meeting of EMA’s human medicines committee (#CHMP) to discuss COVID-19 vaccine Moderna has started. We will communicate the outcome. Follow our updates on Twitter.— EU Medicines Agency (@EMA_News) January 6, 2021
On Monday, The CHMP called an unscheduled meeting to discuss the Coronavirus vaccine from Moderna, however, it failed to reach a conclusion.
The medicines authority of Europe could not specify why it was unable to approve the vaccine, however, on Tuesday, its experts said they were “working hard to clarify outstanding issues with the company”.
The Dutch national medicines authority spoke a leading International news agency, Reuters, and said it was preparing for both a positive decision on Wednesday and for a scenario in which a conclusion still could not be reached.
The EMA had set 12th of January as the deadline to come to a conclusion on the Moderna Vaccine.
However, EMA has approved the Moderna vaccine today itself, and tweeted, “Good news for our efforts to bring more #COVID19 vaccines to Europeans! @EMA_News assessed that the @moderna_tx vaccine is safe & effective. Now we are working at full speed to approve it & make it available in the EU.”
Good news for our efforts to bring more #COVID19 vaccines to Europeans!— Ursula von der Leyen (@vonderleyen) January 6, 2021
@EMA_News assessed that the @moderna_tx vaccine is safe & effective.
Now we are working at full speed to approve it & make it available in the EU.
It recommended a COVID-19 vaccine from Pfizer and its German partner BioNTech on the 21st of December.
The report said, “A positive decision would mark the second regulatory authorisation for Moderna’s vaccine after the United States and further validation of its messenger RNA technology, just over a year since the first outbreak of the virus was identified in Wuhan, China,” from Mint.
The report also said that the vaccine was around 95% effective at preventing the illness in the clinical trials which also showed no serious safety issue.
Since its roll out, a week ago, in the European Union hundreds of thousands of Europeans have received the vaccine from Pfizer-BioNTech.
Over 10 lakh (1 million) shots have been distributed in the United Kingdom alone, in less than a month and the uneven beginning of the campaign has led to criticism of health authorities in several countries such as Germany and France.
On Wednesday, the Netherlands started the vaccinations and gave the first shot of the vaccination to a 39 year old case home nurse.